Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionAviso Wealth Management
Latest Disclosed Ownership460 shares
Latest Disclosed Value $ 355,414
Aviso Wealth Management reports 6.88% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 8, 2026 - Aviso Wealth Management filed a 13F-HR form disclosing ownership of 460 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $355,414 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 494 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -6.88% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 460 -34 -6.88 355 -6.82 0.1602
2026-02-13 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 494 -68 -12.10 381 20.95 0.1603
2025-11-14 2025-09-30 13F REGENERON PHARMACEUTICALS OM 75886F107 562 -626 -52.69 316 -49.44 0.1377
2025-08-11 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,188 -1,496 -55.74 624 -63.40 0.2912
2025-05-09 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,684 10 0.37 1,702 -10.61 0.9048
2025-02-12 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,674 1,054 65.06 1,905 11.80 0.9717
2024-11-07 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,620 -25 -1.52 1,703 -1.45 0.9238
2024-08-15 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,645 361 28.12 1,729 39.92 1.0263
2024-05-14 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,284 418 48.27 1,236 62.50 0.7793
2024-02-13 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 866 866 761 0.5512
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.